OakChart

Acrivon Therapeutics Inc

ACRVHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 9:51 AM ET

1.59+0.02 (1.27%)
2026-11-11 15:53 CET
Market cap
67.28 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-74.22 USD m
Free cash flow, TTM
-64.14 USD m
EPS diluted, TTM
-1.89
P/E
-
Compare

Price

ACRV against its 20, 50 and 200-day averages
2050200beatmiss
1.501.752.002.25751K1.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ACRVclose 1.5920-day 1.6950-day 1.86200-day 1.751.59

55.3% under 3.56 on 7 Jan 2026. Last 15 sessions, 25.7% high to low

Profile

ACRV
52-week range, 14% of the way up
1.273.56

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Employees76
IPONov 15, 2022
Beta1.98
ATR, 14d0.13
Rel volume1.01
Short float5.43%
Insider own22.47%
Inst own45.86%

Snapshot

6 groups

Valuation

Index-
Market Cap68.14M
Enterprise Value-19.70M
Income-74.22M
Sales0.00M
Book/sh2.02
Cash/sh2.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPONov 15, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.79
P/C0.76
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.99
Current Ratio7.99
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.89
EPS next Y-1.59
EPS next Q-0.44
EPS this Y8.42%
EPS next Y13.90%
EPS next 5Y14.02%
EPS past 3/5Y-12.47% -51.39%
Sales past 3/5Y- -
EPS Y/Y TTM16.04%
Sales Y/Y TTM-
EPS Q/Q21.40%
Sales Q/Q-
EarningsAug 12 AMC
EPS/Sales Surpr.14.38% -

Ownership

Insider Own22.47%
Insider Trans-0.20%
Inst Own45.86%
Inst Trans3.46%
ROA-57.61%
ROE-64.63%
ROIC-84.69%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.94%
SMA50-14.35%
SMA200-9.31%
Trades-

Technical

Shs Outstand42.85M
Shs Float33.22M
Short Float5.43%
Short Ratio6.24
Short Interest1.80M
52W High3.56 -55.34%
52W Low1.27 25.20%
Volatility10.43% 7.57%
ATR (14)0.13
RSI (14)40.24
Beta1.98
Rel Volume1.01
Avg Volume289.12K
Volume29,495

Performance

Perf Week-8.62%
Perf Month-9.14%
Perf Quarter-14.05%
Perf Half Y-17.19%
Perf YTD-34.02%
Perf Year-23.19%
Perf 3Y-63.66%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price11.50
Prev Close1.57
Price1.59
Change %1.27%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
May 05, 2025ResumedPPiper SandlerOverweight$6+277.4%
Jan 31, 2025InitiatedKKeyBanc Capital MarketsOverweight
Sep 16, 2024UpgradeLLadenburg ThalmannNeutral → Buy$16+906.3%
Apr 29, 2024DowngradeLLadenburg ThalmannBuy → Neutral
Mar 01, 2024InitiatedJJMP SecuritiesMkt Outperform$14+780.5%
Dec 15, 2023ResumedJJefferiesBuy$17 → $12+654.7%
Oct 05, 2023InitiatedMMaxim GroupBuy
Jun 02, 2023InitiatedOOppenheimerOutperform$25+1,472.3%
May 08, 2023InitiatedBBMO Capital MarketsOutperform$25+1,472.3%
Apr 27, 2023InitiatedLLadenburg ThalmannBuy$22+1,283.6%

Peers

Mkt cap
TickerCompanyMkt cap
ZNTLZentalis Pharmaceuticals Inc185.72M
APREAprea Therapeutics Inc6.23M
IDYAIdeaya Biosciences Inc3.06B
TNGXTango Therapeutics Inc4.16B
BDTXBlack Diamond Therapeutics Inc93.36M
OKUROnKure Therapeutics Inc137.30M
CRDFCardiff Oncology Inc60.69M
ERASErasca Inc5.66B
MAIAMAIA Biotechnology Inc66.08M
SDGRSchrodinger Inc2.47B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Miller MaryChief Legal OfficerOct 22 '26Sale1.8451394481,202Oct 26 04:03 PM
Miller MaryChief Legal OfficerOct 05 '26Sale1.9929458581,715Oct 07 05:02 PM
Blume-Jensen PeterPresident and CEOAug 25 '26Sale2.2114,03630,9692,230,052Aug 27 04:14 PM
Peter Blume-JensenOfficerAug 25 '26Proposed Sale2.1814,03630,598Aug 25 08:40 PM
Peterson KatharineChief Accounting OfficerAug 18 '26Sale2.0110120318,033Aug 20 04:10 PM
Miller MaryChief Legal OfficerAug 18 '26Sale2.0118537282,009Aug 20 04:09 PM
Gamelin ErickChief Development OfficerAug 18 '26Sale2.0140080452,592Aug 20 04:08 PM
Devroe EricChief Operating OfficerAug 18 '26Sale2.016041,214146,349Aug 20 04:07 PM
Blume-Jensen PeterPresident and CEOAug 18 '26Sale2.011,2292,4702,244,088Aug 20 04:07 PM
Blume-Jensen PeterPresident and CEOAug 18 '26Sale2.01484973385,859Aug 20 04:07 PM
Levy Adam D.Chief Financial OfficerAug 04 '26Sale1.571,1421,79366,008Aug 06 04:34 PM
Miller MaryChief Legal OfficerJul 21 '26Sale1.765731,00882,194Jul 23 04:28 PM
Blume-Jensen PeterPresident and CEOJan 14 '26Buy1.6849,00082,1242,095,771Jan 16 04:02 PM
Levy Adam D.Chief Financial OfficerJan 14 '26Buy1.708,83214,99920,983Jan 16 04:01 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DXUVUS Vector Equity Portfolio ETF Class Shares-

News

latest 14 of 202
  • Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKC? Inhibitor Preclinical Program from Aqilion AB (GlobeNewswire)
  • Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.77%
  • Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium (GlobeNewswire)
  • Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 (GlobeNewswire) +6.21%
  • Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Loading…
  • Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer (GlobeNewswire)
  • Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts (GlobeNewswire) +7.56%
  • Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study (GlobeNewswire) +5.13%
  • Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference (GlobeNewswire)
  • Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit (GlobeNewswire)
  • Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.81% -6.78%
  • Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts (GlobeNewswire)
  • Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities (GlobeNewswire) +6.59%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.430-0.502-0.4050.000.008
2026Q12026-05-13-0.490-0.525-0.4920.000.287
2025Q42026-03-19-0.490-0.483-0.4910.000.179
2025Q32025-11-13-0.470-0.591-0.4730.000.009
2025Q22025-08-13-0.550-0.568-0.5460.000.009
2025Q12025-05-14-0.510-0.643-0.5130.000.008
2024Q42025-03-27-0.600-0.664-0.5970.000.009
2024Q32024-11-13-0.590-0.578-0.5890.000.0010
2024Q22024-08-13-0.520-0.603-0.5200.000.008
2024Q12024-05-14-0.730-0.840-0.7300.000.0010
2023Q42024-03-28-0.860-0.728-0.8620.000.0010
2023Q32023-11-09-0.660-0.708-0.6550.000.008
2023Q22023-08-11-0.630-0.648-0.6330.000.005
2023Q12023-05-09-0.580-0.651-0.5820.000.005
2022Q42023-03-28-0.800-0.810-0.4280.000.001
2022Q32023-03-10-5.170--0.4400.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-7.560-4.820-1.4220.000.00
2023FY-2.740-2.623-2.7350.000.00
2024FY-2.380-2.515-2.3840.000.00
2025FY-2.020-2.025-2.0200.000.15
2026FY--1.850--0.00
2027FY--1.593--0.00
2028FY--1.284--13.79
2029FY--1.088--39.89
2030FY--0.555--102.34

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-225000.000.000.00
2026Q3S2026-08-224000.000.000.00
2026Q3S2026-08-135000.000.000.00
2026Q3S2026-08-125000.000.000.00
2026Q3S2026-06-275000.000.000.00
2026Q3S2026-05-146000.500.003.03
2026Q3S2026-04-016000.500.003.03
2026Q3S2026-03-197000.430.003.03
2026Q3S2026-01-076000.000.000.00
2026Q3S2025-11-145000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00

Estimate history

EPS, annual-0.254-0.779-1.422-2.735-2.384-2.023-1.885
Period202020212022202320242025TTM
EPS, quarterly-0.52-0.589-0.597-0.513-0.546-0.473-0.491-0.492-0.429
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual20.8620.8621.92122.52331.23131.64942.847
Period202020212022202320242025MRQ
Shares, quarterly30.96631.13131.23131.35231.4531.5531.64938.74542.847
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.441.361.010.541.090.830.01
Gross Profit-1.44-1.36-1.01-0.54-1.09-0.83-0.01
Selling, General and Administrative Excl. Other76.9382.7688.1966.7032.1015.643.15
Research and Development55.9658.6362.9945.4923.5913.681.86
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-78.37-84.11-89.20-67.24-33.19-16.48-3.17
Interest Expense0.000.000.000.000.00--
Unusual Expense0.000.000.000.000.00-0.022.17
Net Income Before Taxes-74.22-77.91-80.56-60.39-31.17-16.24-5.31
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-74.22-77.91-80.56-60.39-31.17-16.24-5.31
Net Income From Continuing Operations-74.22-77.91-80.56-60.39-31.17-16.24-5.31
Net Income-74.22-77.91-80.56-60.39-31.17-16.24-5.31
EPS (Recurring)-1.77-2.02-2.38-2.74-1.42-0.78-0.18
EPS (Basic, Before Extraordinaries)-1.89-2.02-2.38-2.74-1.42-0.78-0.25
EPS (Diluted)-1.89-2.02-2.38-2.74-1.42-0.78-0.25
EBITDA-76.93-82.76-88.19-66.70-32.10-15.64-3.15
Non-Operating Income (Expense)4.156.218.646.852.030.210.03
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense11.4014.7214.2911.622.190.500.00
Shares Outstanding42.8531.6531.2322.5221.9220.8620.86
Market Capitalization67.2867.28187.44108.75240.59240.59-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.400.380.360.300.300.310.300.30
Gross Profit-0.40-0.38-0.36-0.30-0.30-0.31-0.30-0.30
Selling, General and Administrative Excl. Other18.2719.5219.7519.3922.3521.3524.6524.84
Research and Development13.4414.7814.3813.3515.8815.1018.3318.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.67-19.90-20.12-19.69-22.65-21.66-24.95-25.14
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-17.96-19.04-18.98-18.23-21.01-19.68-22.83-22.44
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-17.96-19.04-18.98-18.23-21.01-19.68-22.83-22.44
Net Income From Continuing Operations-17.96-19.04-18.98-18.23-21.01-19.68-22.83-22.44
Net Income-17.96-19.04-18.98-18.23-21.01-19.68-22.83-22.44
EPS (Recurring)-0.43-0.49-0.49-0.47-0.55-0.51-0.60-0.59
EPS (Basic, Before Extraordinaries)-0.43-0.49-0.49-0.47-0.55-0.51-0.60-0.59
EPS (Diluted)-0.43-0.49-0.49-0.47-0.55-0.51-0.60-0.59
EBITDA-18.27-19.52-19.75-19.39-22.35-21.35-24.65-24.84
Non-Operating Income (Expense)0.700.861.131.451.641.982.122.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.212.183.093.913.933.793.713.67
Shares Outstanding42.8538.7531.6531.5531.4531.3531.2331.13
Market Capitalization67.2853.8576.0556.9337.3163.64187.44216.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments118.58179.48127.46127.7599.601.58
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.862.152.234.340.810.14
Total Current Assets120.44181.63129.69132.09100.411.72
Net Property, Plant & Equipment7.428.037.916.865.790.06
Total Investments and Advances0.205.290.4142.270.390.41
Intangible Assets--0.000.000.000.00
Deferred Tax Assets1.10-----
Other Assets1.651.650.250.000.000.00
Total Assets130.82196.59138.26181.23106.592.19
Short Term Debt Incl. Current Port. of LT Debt1.171.060.880.730.660.06
Accounts Payable2.280.765.050.900.960.14
Other Current Liabilities12.2115.407.384.891.290.42
Total Current Liabilities15.6617.2113.306.522.910.61
Long Term Debt1.542.593.774.24127.489.98
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.10-----
Other Liabilities0.000.000.000.000.000.00
Total Liabilities18.3019.8017.0710.75130.4010.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity112.52176.79121.19170.47-23.81-8.41
Total Shareholders Equity112.52176.79121.19170.47-23.81-8.41
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity112.52176.79121.19170.47-23.81-8.41
Total Liabilities & Stockholders Equity130.82196.59138.26181.23106.592.19
Book Value Per Share3.565.665.387.78-1.14-0.40
Tangible Book Value Per Share3.565.665.387.78-1.14-0.40
Full-Time Employees76785841--
Price to Book Ratio0.780.950.79-5.27-5.27-
Return on Assets-47.59-48.11-37.80-21.66-29.87-
Return on Equity-53.86-54.07-41.41-42.50--
Return on Invested Capital-68.31-44.91-48.33-17.84-15.67-337.53
Quick Ratio7.6910.559.7520.2734.462.80
Current Ratio7.6910.559.7520.2734.462.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-74.22-77.91-80.56-60.39-31.17-16.24-5.31
Depreciation1.501.361.010.541.090.830.01
Other Funds (Non Cash)12.7915.3111.449.071.491.102.17
Funds from Operations-59.94-61.24-68.11-50.78-28.59-14.31-3.12
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-2.98-2.432.448.14-1.530.330.32
Cash from Operating Activities-62.92-63.66-65.67-42.64-30.12-13.98-2.80
Capital Expenditures-1.22-1.67-2.77-1.29-2.17-0.24-0.01
Net Assets From Acquisitions-0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.00
Purchase or Sale of Investments56.7367.77-49.0052.01-139.510.000.00
Purchase of Investments-73.27-81.73-202.93-56.53-150.180.000.00
Sale Or Maturity of Investments130.00149.50153.92108.5310.670.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities55.5166.10-51.7750.72-141.68-0.24-0.01
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock7.300.00123.55-0.26101.71112.222.83
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock7.300.00123.55-0.26101.71112.222.83
Proceedsfrom Stock Options7.290.0063.45-1.03101.69112.222.83
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.06
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.38-0.75-2.52-1.300.000.000.00
Other Financing Activities Uses-0.38-0.75-2.52-1.300.000.000.00
Cash from Financing Activities6.93-0.75121.03-1.55101.71112.222.89
Net Change in Cash-0.481.693.596.52-70.0898.000.07
Free Cash Flow-64.14-65.33-68.44-43.93-32.28-14.22-2.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments89.9697.74118.58129.25137.42149.63
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.531.481.861.110.991.69
Total Current Assets91.4999.22120.44130.36138.41151.33
Net Property, Plant & Equipment6.226.917.427.988.127.98
Total Investments and Advances0.200.190.205.3110.4015.39
Deferred Tax Assets--1.10---
Other Assets1.181.511.651.651.651.65
Total Assets99.09107.83130.82145.30158.58176.35
Short Term Debt Incl. Current Port. of LT Debt1.141.151.171.181.151.10
Accounts Payable0.861.162.281.001.163.69
Other Current Liabilities9.458.7412.2112.7111.128.75
Total Current Liabilities11.4511.0515.6614.8913.4313.55
Long Term Debt0.981.261.541.802.122.41
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--1.10---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities12.4312.3218.3016.7015.5515.96
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity86.6795.52112.52128.60143.04160.39
Total Shareholders Equity86.6795.52112.52128.60143.04160.39
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity86.6795.52112.52128.60143.04160.39
Total Liabilities & Stockholders Equity99.09107.83130.82145.30158.58176.35
Book Value Per Share2.022.473.564.084.555.12
Tangible Book Value Per Share2.022.473.564.084.555.12
Full-Time Employees--76---
Price to Book Ratio0.780.390.590.400.230.36
Return on Assets-57.61-54.38-47.59-45.42-44.18-56.42
Return on Equity-64.63-60.39-53.86-50.23-47.87-62.41
Return on Invested Capital-20.50-19.68-16.65-13.98-14.47-12.09
Quick Ratio7.998.987.698.7510.3111.17
Current Ratio7.998.987.698.7510.3111.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-17.96-19.04-18.98-18.23-21.01-19.68
Depreciation0.410.380.360.350.340.31
Other Funds (Non Cash)2.552.623.494.144.013.68
Funds from Operations-15.01-16.04-15.14-13.75-16.66-15.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.15-4.49-0.101.470.05-3.85
Cash from Operating Activities-14.86-20.54-15.24-12.28-16.61-19.54
Capital Expenditures-0.09-0.01-0.22-0.90-0.49-0.06
Net Assets From Acquisitions0.000.00--0.000.00
Sale of Fixed Assets and Businesses0.000.00--0.000.00
Purchase or Sale of Investments15.0313.1421.746.8119.9419.27
Purchase of Investments-9.97-16.86-13.26-33.19-15.06-20.23
Sale Or Maturity of Investments25.0030.0035.0040.0035.0039.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities14.9513.1321.525.9119.4519.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.300.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.300.000.000.000.000.00
Proceedsfrom Stock Options7.290.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.03-0.03-0.19-0.12-0.10-0.34
Other Financing Activities Uses-0.03-0.03-0.19-0.12-0.10-0.34
Cash from Financing Activities7.27-0.03-0.19-0.12-0.10-0.34
Net Change in Cash7.35-7.446.09-6.492.74-0.66
Free Cash Flow-14.95-20.55-15.46-13.18-17.10-19.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.43%1.8M33.2M298.61K
2026-10-155.23%1.7M33.2M322.22K
2026-09-304.87%1.6M33.2M381.88K
2026-09-153.62%1.2M33.2M382.99K
2026-08-313.43%1.1M33.2M398.33K
2026-08-143.68%1.2M33.6M409.45K
2026-07-314.02%1.4M33.7M448.43K
2026-07-154.41%1.5M33.7M585.82K
2026-06-308.43%2.8M33.7M571.80K
2026-06-158.39%2.8M33.7M618.75K
2026-05-298.55%2.8M32.8M703.55K
2026-05-157.62%2.5M32.7M787.94K
2026-04-308.38%2.5M29.4M817.90K
2026-04-158.12%2.4M29.4M822.02K
2026-03-318.02%2.2M27.3M1.75M
2026-03-138.83%2.4M27.3M1.70M
2026-02-279.61%2.1M22.2M1.62M
2026-02-1310.48%2.3M22.2M1.56M
2026-01-309.12%2.0M22.2M1.76M
2026-01-1533.88%7.5M22.2M1.62M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-023Initial statement of beneficial ownership of securities2026-08-31SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.53K2
2026-090000
2026-080038.80K8
2026-07001.01K1
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01114.34K300
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.28.57%
Sands Capital Alternatives, LLC5.35%
ACADIAN ASSET MANAGEMENT LLC3.07%
VANGUARD CAPITAL MANAGEMENT LLC2.22%
WELLINGTON MANAGEMENT GROUP LLP2.07%
RENAISSANCE TECHNOLOGIES LLC1.77%
TWO SIGMA INVESTMENTS, LP1.50%
MARSHALL WACE, LLP1.24%
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.69%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.27%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Ultra-Small Company Fund0.74%
Fidelity Extended Market Index Fund0.36%
iShares Micro-Cap ETF0.17%
Ultra-Small Company Market Fund0.14%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.04%
VANGUARD BALANCED INDEX FUND0.04%

OakChart. ACRV. Cached 15 minutes.